Get the Stockscreener App
15.04
1.31%
-0.20
After Hours:
15.02
-0.02
-0.13%
Janux Therapeutics Inc stock is traded at $15.04, with a volume of 984.42K.
It is down -1.31% in the last 24 hours and up +10.75% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$15.24
Open:
$14.68
24h Volume:
984.42K
Relative Volume:
0.80
Market Cap:
$914.91M
Revenue:
$10.00M
Net Income/Loss:
$-113.63M
P/E Ratio:
-8.2033
EPS:
-1.8334
Net Cash Flow:
$-83.28M
1W Performance:
+3.51%
1M Performance:
+10.75%
6M Performance:
-46.82%
1Y Performance:
-48.25%
1-Day Range:
$14.60
$15.13
1-Week Range:
$14.36
$15.50
52-Week Range:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
15.04 | 927.07M | 10.00M | -113.63M | -83.28M | -1.8334 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-10-25 | Initiated | Stifel | Buy |
| Sep-10-25 | Initiated | Truist | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Janux Therapeutics Lacking Near-Term Catalysts, UBS Says - Moomoo
Sector Update: Health Care - Moomoo
Janux Therapeutics (NASDAQ:JANX) Shares Gap DownWhat's Next? - MarketBeat
UBS Downgrades Janux Therapeutics to Neutral From Buy, Adjusts PT to $15 From $57 - Moomoo
Short Interest in Janux Therapeutics, Inc. (NASDAQ:JANX) Decreases By 22.7% - MarketBeat
UBS downgrades Janux Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Evercore Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23 - Moomoo
Insider sales and option exercises reported for JANX (JANX) in Form 144 filing - Stock Titan
Will Janux Therapeutics Inc outperform its industry peersTrade Risk Report & Weekly Hot Stock Watchlists - baoquankhu1.vn
Responsive Playbooks and the JANX Inflection - Stock Traders Daily
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Janux Therapeutics (NASDAQ:JANX) Raised to "Hold" at Wall Street Zen - MarketBeat
Bristol-Myers Squibb Cancer Moves And Equity Efforts Underpin Valuation Case - Yahoo Finance
Janux Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
71,016 shares tied to option exercise at JANX (NASDAQ: JANX) disclosed - Stock Titan
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal - The Globe and Mail
Janux nominates development candidate under BMS collaboration - BioWorld News
Janux Therapeutics receives $35M milestone from Bristol Myers Squibb By Investing.com - Investing.com Australia
Bristol Myers Squibb (BMY) Partners with Janux on New Cancer The - GuruFocus
Janux Unveils Development Candidate in Bristol Myers Squibb Partnership, Worth $35M Milestone - Contract Pharma
Janux Therapeutics Expects $35 Million Milestone Payment From Bristol-Myers Squibb - Moomoo
Janux Therapeutics announces development candidate nomination under Bristol Myers Squibb collaboration - marketscreener.com
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration - TradingView
Janux Therapeutics, Inc. announced that, under its collaboration with Bristol Myers Squibb, it has officially nominated a development candidate drug. - Bitget
Janux Therapeutics receives $35M milestone from Bristol Myers Squibb - Investing.com
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment - Yahoo Finance
Janux Therapeutics (JANX) price target decreased by 11.93% to 54.57 - MSN
Understanding the Setup: (JANX) and Scalable Risk - Stock Traders Daily
Janux reports positive phase 1 results for JANX007 in mCRPC; stock down - MSN
We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely - Moomoo
Janux Therapeutics (NASDAQ:JANX) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Does Janux Therapeutics (NASDAQ:JANX) Show Signs of Market Sensitivity? - Kalkine Media
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
JANX SEC FilingsJanux Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
D-Wave Quantum: Die bittere Wahrheit! - Finanztrends
Advanced Renal Cell Carcinoma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeuti - Barchart.com
The Technical Signals Behind (JANX) That Institutions Follow - Stock Traders Daily
KROS Stock: What to Know About Rinvatercept in DMD - Yahoo Finance
8th T-Cell Engager Therapeutics Summit - inewsource
Precision Trading with Janux Therapeutics Inc. (JANX) Risk Zones - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Veeva Systems (VEEV) and Janux Therapeutics Inc (JANX) - The Globe and Mail
HC Wainwright Expects Higher Earnings for Janux Therapeutics - MarketBeat
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits
JANX PE Ratio & Valuation, Is JANX Overvalued - Intellectia AI
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring The 316.79% Potential Upside - DirectorsTalk Interviews
JANX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Truist cuts Janux Therapeutics stock price target on competition By Investing.com - Investing.com Canada
Truist Securities Adjusts PT on Janux Therapeutics to $80 From $100, Maintains Buy Rating - marketscreener.com
Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating - TipRanks
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):